Black checkmark with a sparkle and a curved line underneath on a white background.
Company

ADC Therapeutics SA

Ticker
ADCT
Sector
Industry
Report date
November 11, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary
Recent developments:
Overview

ADC Therapeutics SA develops and commercializes antibody-drug conjugates, primarily ZYNLONTA, targeting hematologic cancers such as diffuse large B-cell lymphoma. The company generates revenue from product sales in the U.S. and is engaged in clinical trials to expand indications and market opportunities. It has raised capital through private placements and manages royalty obligations under a purchase agreement. The company faces regulatory scrutiny related to clinical trial outcomes and continues to invest in research, development, and commercialization efforts.

Executive summary

ADC Therapeutics SA is a biopharmaceutical company focused on antibody-drug conjugates, with its marketed product ZYNLONTA for relapsed or refractory DLBCL. The company reported Q3 2026 net product revenue of $21.7 million and a net loss of $25.3 million, with cash and equivalents of $189.2 million as of September 30, 2026. Liquidity ratios indicate a strong short-term financial position. Recent clinical trial data raised FDA concerns about the benefit-risk profile of ZYNLONTA in earlier lines of therapy, potentially impacting regulatory approvals and commercial sales. The company is advancing clinical development with plans for Phase III studies and has undertaken financial restructuring and financing to support operations. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for ADCT

Bull case model:

The company has demonstrated revenue growth with a 33% increase in Q3 product revenue and maintains a strong cash position extending its runway into 2029. Positive clinical responses in lymphoma and regulatory filings in new markets like Japan support potential expansion. Financial restructuring and capital raises provide resources to advance clinical programs and commercialization efforts.

Bear case model:

FDA concerns regarding the LOTIS-5 trial's benefit-risk profile may lead to additional confirmatory trials, delaying or limiting approvals in earlier lines of therapy. This could impact sales and the perception of ZYNLONTA's clinical benefit. The company continues to report net losses and relies on capital raises and restructuring to fund operations, which may pressure financial stability if clinical or commercial setbacks occur.

Moat:

ADC Therapeutics' moat is based on its proprietary antibody-drug conjugate technology and its marketed product ZYNLONTA, which has accelerated approval for treatment of relapsed or refractory DLBCL. The company's ongoing clinical development programs aim to expand indications and strengthen its competitive position. However, regulatory challenges and the need for confirmatory trials introduce uncertainty around sustained market exclusivity and commercial success.

Risks overview
Risks summary
The most significant risk is regulatory uncertainty stemming from FDA concerns about clinical trial results, which may affect approvals, sales, and the company's ability to expand indications.
Risks details:

• Regulatory Risk: FDA expressed substantial concerns about the LOTIS-5 trial results, which may require additional confirmatory trials and could affect current and future approvals of ZYNLONTA.
• Clinical Trial Risk: Ongoing and planned clinical trials carry inherent risks including enrollment, outcomes, and regulatory acceptance, impacting product development and market expansion.
• Financial Risk: The company reports net losses and depends on financing and restructuring to support operations, with risks related to liquidity and capital availability.
• Revenue Recognition Risk: Revenue recognition involves significant estimates and judgments related to rebates, chargebacks, and discounts, which could affect reported financial results.

FINAL FORECAST FOR ADCT

Final take one line
Final take 12 to 24 month view
Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • ADC Therapeutics SA is a biopharmaceutical company focused on developing and commercializing antibody-drug conjugates, with its marketed product ZYNLONTA for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
  • The company generates revenue primarily from sales of ZYNLONTA in the U.S. for 3L+ DLBCL patients.
  • As of September 30, 2026, ADC Therapeutics reported net product revenue of $21.7 million for Q3 2026 and a net loss of $25.3 million for the same period.
  • Cash and cash equivalents were $189.2 million as of September 30, 2026, with current assets of $238.6 million and current liabilities of $78.1 million, resulting in a current ratio of 3.05 and a cash ratio of 2.42.
  • The company completed private placements in June and October 2025 raising net proceeds of approximately $150.7 million.
  • ADC Therapeutics has a deferred royalty obligation under a royalty purchase agreement with Healthcare Royalty Partners, accounted for as debt with amortized cost and accretion based on revenue projections.
  • The company is conducting clinical trials for ZYNLONTA in earlier lines of therapy and combination regimens to expand market opportunity.
  • Recent clinical trial data for ZYNLONTA (LOTIS-5 trial) raised FDA concerns about benefit-risk profile and clinical benefit verification, potentially impacting regulatory approvals and commercial sales.
  • ADC Therapeutics announced financial restructuring and additional financing in 2026 to support operations and clinical development.
  • The company has filed for regulatory approval of ZYNLONTA in Japan for relapsed or refractory lymphoma.
  • The company plans a Phase III study following strong lymphoma responses reported in clinical trials.
  • The FDA's concerns about LOTIS-5 trial results may require additional confirmatory trials, which involve significant time and resources.
  • The company’s primary uses of capital include research and development, selling and marketing, compensation, debt servicing, and other operating expenses.
  • The company recognizes revenue net of gross-to-net adjustments including rebates, chargebacks, and discounts, which require significant estimates and judgment.
  • The company has no off-balance sheet arrangements as of the latest filings.
  • Financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.
Sources
Sources - Context summary

Generated 2026-11-11

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-10 | 10-K
  • S2 | 2026-11-09 | 10-Q
Sources - News headlines
  • N1 | 2026-11-09 | www.nasdaq.com | ADC Therapeutics SA Reports Third Quarter 2026 Net Product Revenue of $21.0 million and Cash of $189.2 million | https://www.nasdaq.com/articles/adc-therapeutics-sa-reports-third-quarter-2026-net-product-revenue-210-million-and-cash
  • N2 | 2026-11-09 | www.nasdaq.com | ADC Therapeutics Q3 Product Revenue Rises 33%; Cash Runway Extends Into 2029; Stock Down | https://www.nasdaq.com/articles/adc-therapeutics-q3-product-revenue-rises-33-cash-runway-extends-2029-stock-down
  • N3 | 2026-11-09 | www.nasdaq.com | ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates | https://www.nasdaq.com/articles/adc-therapeutics-sa-adct-reports-q3-loss-tops-revenue-estimates
  • N4 | 2026-11-05 | www.nasdaq.com | BioAge Labs, Inc. (BIOA) Reports Q3 Loss, Misses Revenue Estimates | https://www.nasdaq.com/articles/bioage-labs-inc-bioa-reports-q3-loss-misses-revenue-estimates
  • N5 | 2026-11-05 | www.nasdaq.com | ADC Therapeutics SA Announces ZYNLONTA Clinical Trial Data and Financial Restructuring | https://www.nasdaq.com/articles/adc-therapeutics-sa-announces-zynlonta-clinical-trial-data-and-financial-restructuring
  • N6 | 2026-11-04 | www.nasdaq.com | ADC Therapeutics Reports Strong Lymphoma Responses, Plans Phase III Study | https://www.nasdaq.com/articles/adc-therapeutics-reports-strong-lymphoma-responses-plans-phase-iii-study
  • N7 | 2026-10-29 | www.nasdaq.com | ADC Therapeutics Announces Japan Filing For ZYNLONTA In Relapsed Or Refractory Lymphoma | https://www.nasdaq.com/articles/adc-therapeutics-announces-japan-filing-zynlonta-relapsed-or-refractory-lymphoma
  • N8 | 2026-10-28 | www.nasdaq.com | NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates | https://www.nasdaq.com/articles/neogenomics-neo-q3-earnings-and-revenues-beat-estimates
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine